^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    amlodipine/atorvastatin

    i
    Other names: CI-1038
    Company:
    Generic mfg.
    Drug class:
    HMG-CoA reductase inhibitor, Ca2+ channel antagonist
    Related drugs:
    4ms
    Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (clinicaltrials.gov)
    P4, N=1200, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Dec 2026 --> Sep 2026
    Trial primary completion date
    |
    amlodipine/atorvastatin
    6ms
    Predictors of Significant High-Sensitivity C-Reactive Protein Reduction After Use of Rosuvastatin/Amlodipine and Atorvastatin/Amlodipine-Subgroup Analysis in Randomized Controlled Trials. (PubMed, J Clin Med)
    In patients with ATV, RSV/AML polypill, baseline hsCRP ≥ 2 mg/dL, and baseline RSV 20 mg/AML 5 mg were independent predictors of a significant hsCRP reduction. BMI was not associated with hsCRP reduction (Clinical trial: NCT03951207).
    Journal
    |
    CRP (C-reactive protein)
    |
    amlodipine/atorvastatin
    12ms
    Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese with Hypertension and Atrial Fibrillation (clinicaltrials.gov)
    P4, N=1200, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    amlodipine/atorvastatin
    over1year
    STOP-PA: Statin Combined With Amlodipine Treats Primary Aldosteronism (clinicaltrials.gov)
    P4, N=150, Not yet recruiting, Third Military Medical University
    New P4 trial
    |
    amlodipine/atorvastatin
    2years
    Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. (PubMed, J Clin Hypertens (Greenwich))
    There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg. In conclusion, while maintaining safety, RSV 10 mg/AML 5 mg and the RSV 20 mg/AML 5 mg more effectively reduced LDL-C compared with the ATV 20 mg /AML 5 mg (Clinical trial: NCT03951207).
    P4 data • Journal
    |
    amlodipine/atorvastatin